Manila Times Business
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from Investigator-led pediatric study- -Second indication for QRX003, in addition to Netherton Syndrome- ASHBURN, Va., June 02, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the s
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Diamond drilling program under way at Leviathan Metals’ Central Project, Kalahari Copper Belt, Botswana
1h ago
Paychex Small Business Jobs Index Improves for a Third Consecutive Month
1h ago
Safe Pro Awarded U.S. Army Order For AI-Powered Threat Analysis Kit Together with Red Cat Black Widow Drones
1h ago
Braiin Targets US$3 Trillion Global Residential Services Market Through ClearBank Embedded Banking Infrastructure Integrated into Home.cc Via Strategic Collaboration
1h ago